What alternative antibiotic should be used when ceftolozane/tazobactam is unavailable?

Alternative Antibiotics When Ceftolozane/Tazobactam is Unavailable

For difficult-to-treat Pseudomonas aeruginosa (DTR-PA) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), ceftazidime/avibactam 2.5 g IV q8h is the preferred alternative to ceftolozane/tazobactam, with colistin-based combination therapy as a second-line option. 1

Primary Alternative: Ceftazidime/Avibactam

Ceftazidime/avibactam represents the most direct alternative with comparable activity against multidrug-resistant Pseudomonas aeruginosa:

• Dosing: 2.5 g IV q8h infused over 3 hours 1
• Indications: Any clinical syndrome due to DTR-PA, including hospital-acquired pneumonia, ventilator-associated pneumonia, bloodstream infections, and complicated urinary tract infections 1
• Evidence level: Weak recommendation, low quality of evidence (2C) 1
• Clinical performance: Recent 2025 data demonstrates that antipseudomonal cephalosporins (including both ceftolozane/tazobactam and ceftazidime/avibactam) significantly reduced 30-day mortality risk by 17% in ICU patients with P. aeruginosa bacteremia 2

Second-Line Alternative: Colistin-Based Combination Therapy

When ceftazidime/avibactam is also unavailable or the organism is resistant, colistin-based combination therapy is recommended 1:

• Loading dose: 5 mg CBA/kg IV loading dose 1
• Maintenance dose: 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h 1
• Combination partners:
  • Meropenem 2 g IV q8h by extended infusion (if carbapenem MIC ≤32 mg/L) 1
  • Tigecycline 100 mg IV loading dose, then 50 mg IV q12h 1
• Evidence level: Weak recommendation, low quality of evidence (2C) 1
• Critical monitoring: Renal function must be closely monitored during colistin therapy due to nephrotoxicity risk 1

Third-Line Alternative: Imipenem/Cilastatin/Relebactam

For DTR-PA when other options are unavailable:

• Dosing: 1.25 g IV q6h 1
• Evidence level: Weak recommendation, low quality of evidence (2C) 1
• Availability note: This agent was not approved by Taiwan FDA as of 2022, so regional availability should be verified 1

Context-Specific Alternatives for CRPA Susceptible to Other Agents

If the organism is carbapenem-resistant but susceptible to traditional agents, consider these options 1:

• Piperacillin/tazobactam: 3.375-4.5 g IV q6h (2D) 1
• Ceftazidime: 2 g IV q8h (2D) 1
• Cefepime: 2 g IV q8-12h (2D) 1
• Fluoroquinolones: Ciprofloxacin 400 mg IV q8h or levofloxacin 750 mg IV qd (2D) 1
• Aminoglycosides: Amikacin 15 mg/kg IV qd (for urinary tract infections only as monotherapy) 1

Treatment Duration

Duration should be tailored to infection site 1:

• Complicated UTI and intra-abdominal infections: 5-10 days 1
• Hospital-acquired/ventilator-associated pneumonia and bloodstream infections: 10-14 days 1
• Individualization factors: Source control adequacy, underlying comorbidities, and initial response to therapy 1

Critical Considerations for Combination Therapy

Combination therapy may be protective in septic shock but should be discontinued within 3-5 days based on clinical improvement 3, 2:

• Recent 2025 ICU data showed combination therapy reduced mortality by 66% specifically in septic shock patients 2
• However, after adjustment for confounders, combination therapy did not show benefit in non-shock patients 2
• Aminoglycosides (tobramycin) provide better coverage than fluoroquinolones when combined with β-lactams for empiric therapy, with cumulative susceptibility rates of 94-95% versus 85-86% for fluoroquinolone combinations 4

Common Pitfalls to Avoid

• Do not use aminoglycoside monotherapy except for urinary tract infections 1
• Monitor for resistance development during therapy with extended-spectrum β-lactams, particularly with Enterobacter, Pseudomonas, and Serratia species 5
• Verify antimicrobial susceptibility testing results before finalizing therapy, as resistance patterns vary significantly 1
• Avoid tigecycline monotherapy for pneumonia; it should only be used in combination if MIC ≤2 mg/L 1